晚期肾细胞癌的治疗 - Suppr

Suppr

超能文献

Treatment of Advanced Renal-Cell Carcinoma.

作者信息

Motzer Robert J, Escudier Bernard, Choueiri Toni K

出版信息

N Engl J Med. 2016 Mar 3;374(9):889-90. doi: 10.1056/NEJMc1515613.

DOI:10.1056/NEJMc1515613

PMID:26962911

Abstract

摘要

相似文献

Treatment of Advanced Renal-Cell Carcinoma.

N Engl J Med. 2016 Mar 3;374(9):889-90. doi: 10.1056/NEJMc1515613.

Treatment of Advanced Renal-Cell Carcinoma.

N Engl J Med. 2016 Mar 3;374(9):888. doi: 10.1056/NEJMc1515613.

Treatment of Advanced Renal-Cell Carcinoma.

N Engl J Med. 2016 Mar 3;374(9):888-9. doi: 10.1056/NEJMc1515613.

Nivolumab: The New Second Line Treatment for Advanced Renal-cell Carcinoma Commentary on: Nivolumab Versus Everolimus in Advanced Renal-cell Carcinoma.

Urology. 2016 Mar;89:8-9. doi: 10.1016/j.urology.2015.12.003. Epub 2015 Dec 23.

Words of Wisdom. Re: Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Eur Urol. 2016 Mar;69(3):538-9. doi: 10.1016/j.eururo.2015.12.025.

Words of Wisdom. Re: Nivolumab Versus Everolimus in Advanced Renal-Cell Carcinoma.

Eur Urol. 2016 Apr;69(4):753-4. doi: 10.1016/j.eururo.2016.01.018. Epub 2016 Feb 18.

Kidney cancer: CheckMate for advanced-stage ccRCC? Nivolumab and cabozantinib aMETEORate poor survival.

Nat Rev Clin Oncol. 2015 Nov;12(11):621. doi: 10.1038/nrclinonc.2015.178. Epub 2015 Oct 13.

CheckMate for advanced-stage ccRCC? Nivolumab and cabozantinib aMETEORate poor survival.

Nat Rev Urol. 2015 Dec;12(12):651. doi: 10.1038/nrurol.2015.246. Epub 2015 Oct 13.

Renal-Cell Cancer--Targeting an Immune Checkpoint or Multiple Kinases.

N Engl J Med. 2015 Nov 5;373(19):1872-4. doi: 10.1056/NEJMe1511252. Epub 2015 Sep 25.

Trials probe new agents for kidney cancer.

JAMA. 2006 Jul 12;296(2):155-7. doi: 10.1001/jama.296.2.155.

引用本文的文献

A Durable Response With the Combination of Nivolumab and Cabozantinib in a Patient With Metastatic Paraganglioma: A Case Report and Review of the Current Literature.

Front Endocrinol (Lausanne). 2020 Nov 27;11:594264. doi: 10.3389/fendo.2020.594264. eCollection 2020.

The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.

Cancer Immunol Res. 2018 Jul;6(7):758-765. doi: 10.1158/2326-6066.CIR-17-0475. Epub 2018 May 10.

A retrospective comparative study of progression-free survival and overall survival between metachronous and synchronous metastatic renal cell carcinoma in intermediate- or poor-risk patients treated with VEGF-targeted therapy.

Oncotarget. 2017 Sep 6;8(55):93633-93643. doi: 10.18632/oncotarget.20674. eCollection 2017 Nov 7.

Modulation of cabozantinib efficacy by the prostate tumor microenvironment.

Oncotarget. 2017 Sep 23;8(50):87891-87902. doi: 10.18632/oncotarget.21248. eCollection 2017 Oct 20.

Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy.

Drug Des Devel Ther. 2017 Apr 11;11:1175-1182. doi: 10.2147/DDDT.S110209. eCollection 2017.

Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice.

Urol Oncol. 2017 Apr;35(4):142-148. doi: 10.1016/j.urolonc.2017.01.017. Epub 2017 Mar 2.

Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions.

Oncotarget. 2017 Mar 21;8(12):20113-20121. doi: 10.18632/oncotarget.15390.

A feed-forward loop between lncARSR and YAP activity promotes expansion of renal tumour-initiating cells.

Nat Commun. 2016 Nov 25;7:12692. doi: 10.1038/ncomms12692.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验